NA
ICPT

NewEdge Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

NewEdge Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,738
Closed -$220K – 728
2018
Q3 		$220K Buy
+1,738
New +$184K 0.02% 589

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NewEdge Advisors's ICPT Position: Q4 2018 in Review

NewEdge Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2018, closing a stake of 1,738 shares — an estimated $220K sold.

NewEdge Advisors first reported a position in ICPT in Q3 2018 and held it in 1 quarter. The position peaked at $220K in Q3 2018. 191 funds tracked by Wall St. Rank hold ICPT as of Q4 2018.

  • NewEdge Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • NewEdge Advisors sold 1,738 Intercept Pharmaceuticals, Inc. shares in Q4 2018, an estimated $220K.
  • NewEdge Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • NewEdge Advisors's Intercept Pharmaceuticals, Inc. position peaked at $220K in Q3 2018.
  • 191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2018.

Based on NewEdge Advisors's 13F filing for Q4 2018, filed 29 Jan 2019.